Management and treatment of<unk>  is case specific and the application of glucocorticoid treatment is not standard as it is in classic CAH.<unk>  is not a life-threatening medical condition and the risks of treatment given prenatally or to asymptomatic children outweigh potential benefits. In appropriate cases, glucocorticoids (usually hydrocortisone in children) are administered to suppress secretion of corticotropin releasing hormone (CRH) produced by hypothalamus and of adrenocorticotropic hormone (ACTH) produced by pituitary gland. This suppression will reduce concentration in blood of sex steroids produced by adrenal glands. Some of the main considerations in treatment include the watchful waiting of symptom severity as well as adverse responses to glucocorticoids administered as drugs, seen in patient bone mineral density, height and weight. For women, an oral contraceptive pill and androgen blockers such as spironolactone or cyproterone acetate are alternatives to glucocorticoids for managing symptoms of androgen excess. Women with<unk>  being treated with hydrocortisone have a lower miscarriage risk.
Late onset congenital adrenal hyperplasia
Lipoid congenital adrenal hyperplasia
Congenital adrenal hyperplasia
Primary pigmented nodular adrenocortical disease
Multiple endocrine neoplasia type 1
Multiple endocrine neoplasia type 2
Multiple endocrine neoplasia
Persistent adrenarche syndrome